US EditionPublished • loading... • Updated
Eli Lilly sees 2026 profit above estimates on weight‑loss drug demand
Eli Lilly expects strong profit growth in 2026 driven by obesity drug sales and the launch of an oral weight-loss pill under FDA review, with quarterly revenue surpassing $19 billion.
- On Feb 4, Eli Lilly forecast 2026 profit above Wall Street estimates, citing surging demand for its obesity drugs and the upcoming FDA review of orforglipron.
- Driven by Zepbound's popularity, the obesity market has shifted toward cash‑pay options and telehealth, helping Lilly last year reach a $1 trillion valuation.
- Data on Mounjaro and Zepbound sales underpinned the beats as the fourth quarter reported profit per share was $7.54, beating analysts' expectation of $6.67 and revenue reached $19.3 billion versus $17.96 billion.
- Shares rose nearly 7% in premarket trading following the report as Lilly raised its adjusted EPS guidance to $33.50 to $35 per share, above analysts' estimate of $33.23.
- Amid government pricing deals, Lilly plans a $399 cap for higher doses while web prices shift to $199–$299 after political pressure, showing cash-pay strategy shifts.
Insights by Ground AI
Podcasts & Opinions
8 Articles
8 Articles
Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars
Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, betting on surging demand for its obesity drugs as the world's most valuable drugmaker prepares to launch its oral weight-loss pill later this year.
·United Kingdom
Read Full Article
Coverage Details
Total News Sources8
Leaning Left1Leaning Right0Center6Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
14%
C 86%
Factuality
To view factuality data please Upgrade to Premium
